BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$67.94+1.55 (+2.33%)
Close on Oct 19, 2026
- Market cap
- $13.30B
- P/E (TTM)
- –
- Dividend yield
- –
BridgeBio Pharma, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q1 23 | Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $243.68M | $194.52M | $154.18M | $120.70M | $110.57M | $116.63M | $5.88M | $2.73M | – | – | – | – | 100.0% | +120.4% |
| Reportable Segment | – | – | – | – | $110.57M | $116.63M | – | – | $2.17M | $211.12M | – | – | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q1 23 | Q4 22 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | -$107.08M | -$105.96M | -$139.56M | -$145.20M | -$134.28M | -$104.37M | -$226.03M | -$191.75M | – | – | – | – | -20.3% |
| Reportable Segment | – | – | – | – | -$134.28M | -$104.37M | – | – | -$175.54M | $343.00K | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q1 23 | Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $222.44M | $180.60M | $146.02M | $108.11M | $71.50M | $36.74M | $2.88M | $0 | – | – | – | $95.00K | 91.3% | +211.1% |
| Royalty revenue | $15.43M | $9.50M | $5.28M | $4.28M | $1.62M | $204.00K | $169.00K | $0 | – | – | – | – | 6.3% | +850.2% |
| License and services revenue | $5.80M | $4.42M | $2.88M | $8.31M | $37.44M | $79.69M | $2.83M | $2.73M | – | – | $1.83M | $1.78M | 2.4% | -84.5% |
| License and Services Revenue | – | – | – | – | $37.44M | $79.89M | – | – | $2.17M | $211.12M | – | – | – | – |
| Net Product Revenue | – | – | – | – | $71.50M | $36.74M | – | – | $0 | $0 | – | – | – | – |
| Royalty Revenue | – | – | – | – | $1.62M | – | – | – | $0 | – | – | – | – | – |
| Attruby | – | – | – | $108.10M | $71.50M | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of BridgeBio Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.